Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma
{{output}}
Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose... ...
